In a recent paper (Ekhtiari et al), researchers performed a cost-utility analysis comparing three carpal tunnel release (CTR) techniques: open (OCTR), endoscopic (ECTR), and ultrasound-guided (CTR-US). The findings of this study highlight that CTR-US is not only more cost-effective ($3,800 vs $8,700), but also associated with faster recovery and improved quality of life. Compared to traditional methods, CTR-US offers shorter recovery times, reducing the overall societal costs, including time off work. This positions CTR-US as a dominant, minimally invasive intervention with substantial cost-saving advantages for patients and healthcare systems alike.

This study emphasizes that as the popularity of minimally invasive procedures grows, CTR-US could be the future standard for carpal tunnel surgery, offering both economic and clinical benefits over traditional open and endoscopic techniques. They concluded the “CTR-US is considered a dominant intervention over both OCTR and ECTR.”

Of note, one limitation of this study is that it focused only on the Sonex CTR-US, but had the study included the Thread CTR-US, the paper’s findings would have been even more dramatic. Using the Thread CTR-US, patients have returned to work as early as post-op day 1, and the cost of the procedure is even less than Sonex. We are fortunate to offer both the Sonex and Thread CTR-US at Boston Sports & Biologics.